|
MPM Capital might be behind that latest medical breakthrough. The investment firm targets biotechnology, specialty pharmaceutical, and medical technology companies. With more than $2 billion of committed capital in four funds, it invests in all stages of a firm's development, typically offering between $5 million and $50 million per transaction, and takes a long-term approach. MPM Capital's portfolio includes about 60 firms, including Affymax, AVEO Pharmaceuticals, Oxagen, and Surface Logix. Most of MPM Capital's investments are in US concerns, but the company also seeks opportunities in Europe, and more recently, Asia and Australia. The company has offices in Boston and San Francisco.
|
| | | Contact Information | |
Address: |
200 Clarendon St., 54th Fl.
Boston, MA 02116
| | Phone: | 617-425-9200 | | Fax: | 617-425-9201 |
|
|
Key People
| | • |
Chairman and Venture Partner:
H. Robert Horvitz
| | • |
Managing Director:
Ansbert K. Gädicke
| | • |
Director Operations and Legal Affairs:
Dana K. O'Brien
|
|
|
